2024 Texas Lung Cancer Conference

Foundation Medicine is delighted to be attending the 2024 Texas Lung Cancer Conference in Austin, Texas, from April 18-20, 2024.

Please stop by Booth #26 to meet our team and see how Foundation Medicine’s testing portfolio can inform treatment decisions for your patients with non-small-cell-lung cancer (NSCLC).

Foundation Medicine’s portfolio provides:

• The only tissue-based test with FDA-approved companion diagnostic claims to detect ROS1, NTRK, ALK, FGFR2, and RET fusions across multiple tumor types.
• More FDA-approved CDx indications for NSCLC than any other testing company*
• An FDA-approved tissue CGP test, with the option to add tissue-informed ctDNA monitoring.